Combined modality treatment of advanced cancers of the oral cavity and oropharynx

Dobrowsky, W.; Dobrowsky, E.; Strassl, H; Braun, Otto; Gritzmann, N.; Schemer, V.

doi:10.1016/0360-3016(91)90097-n

Cited by 25 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survival and locoregional control rates in the presented patient sample are in agreement with previously published data from our institution using the same treatment protocols. 14,15 As in previous studies, 16 -18 in our sample the grades of histopathologic response were also highly associated with survival. This is underlined by the fact that all cases of recurrence were among the nonresponder group, and only half of all nonresponders survived 2 years.…”

Section: Discussionsupporting

confidence: 79%

“…11 -13 Preoperative RCT followed by radical surgery in patients with advanced squamous cell carcinoma of the oral cavity and oropharynx has been in use at our institution since 1985. 14,15 Similar protocols have been published by other groups, 10 yielding comparatively excellent locoregional control rates between 60% and 80%. It has been found that RCT-induced tumor regression is of high prognostic value in patients with oral and oropharyngeal cancer.…”

mentioning

confidence: 80%

See 1 more Smart Citation

Neoadjuvant radiochemotherapy of oral cavity and oropharyngeal cancer: evaluation of tumor response by ct differs from histopathologic response assessment in a significant fraction of patients

et al. 2004

View full text Add to dashboard Cite

Background. Our aim was to compare and assess the predictive value of CT and histopathologic grading of tumor regression at primary tumor sites in patients with squamous cell carcinoma of the oral cavity and oropharynx after neoadjuvant (preoperative) radiochemotherapy (RCT).Methods. We investigated 55 patients with carcinomas of the oral cavity and oropharynx who underwent RCT before curative surgery. Two blinded observers measured RCT-induced reduction of tumor volume in pretherapeutic and posttherapeutic CT scans. Volume changes were compared with histopathologic findings obtained at surgery.Results. Histopathologic response evaluation revealed 31 complete remissions, 12 cases of partial response, and 12 nonresponders. We performed a logistic regression analysis to evaluate whether measured volume reduction could predict the

show abstract

Section: Discussionsupporting

confidence: 79%

mentioning

confidence: 80%

Neoadjuvant radiochemotherapy of oral cavity and oropharyngeal cancer: evaluation of tumor response by ct differs from histopathologic response assessment in a significant fraction of patients

et al. 2004

View full text Add to dashboard Cite

show abstract

“…It was shown that RT is likely to be more effective in otherwise unaffected and well oxygenated tissue 3,9,21 . The concept of administering RCT before surgery has been reported in studies by DOBROWSKY et al 6 , MOHR et al 20 , KIRITA et al 15 , and ECKARDT et al 7 . These authors report 2-year overall survival probabilities ranging from 63 to 86% and 2-year local control probabilities ranging from 68 to 84%.…”

mentioning

confidence: 94%

Preoperative radiochemotherapy and radical resection for stages II–IV oral and oropharyngeal cancer: outcome of 222 patients

Klug

Wutzl

Kermer

et al. 2005

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…Klug et al [26], representing 222 patients, reported an overall survival of 55% after 5 years and a local control probability of 74%. Other publications regarding neoadjuvant treatment modalities report 2-year survival rates between 63 and 86% [1, 2, 13, 22,27,28,29,30]. In postoperative adjuvant treatment regimens, lower survival rates of 50–65% are described [31, 32].…”

Section: Discussionmentioning

confidence: 99%

Preoperative Paclitaxel/Carboplatin Radiochemotherapy for Stage III/IV Resectable Oral and Oropharyngeal Cancer: Seven-Year Follow-Up of a Phase II Trial

Eckardt

Sinikovic²,

Hofele³

et al. 2007

Oncology

View full text Add to dashboard Cite

Numerous treatment concepts for advanced but resectable oral and oropharyngeal squamous cell carcinoma exist. In this study, we present the 7-year results of a promising treatment with preoperative simultaneous chemoradiation using paclitaxel and carboplatin within a prospective phase II trial comprising 56 patients. After determination of the local tumor extension, chemoradiation was applied for 4 weeks and up to 40 Gy. Following a recovery period of 3–4 weeks, tumor resection was performed within the initially tattooed resection margins, together with a functional modified neck dissection. The median follow-up time was 44.9 ± 19.6 months (range 0.76–87.9). After 7 years, 35 (63.3%) patients were alive and 20 (36.4%) had died. In 2 patients (3.6%), the cause of death was related to treatment. After 7 years, the overall survival rate declined to 63.6%, whereas the local recurrence-free probability was still 84.2%. These results confirm the excellent local control and high survival rates of preoperative radiochemotherapy with the combination of paclitaxel/carboplatin.

show abstract

Combined modality treatment of advanced cancers of the oral cavity and oropharynx

Cited by 25 publications

References 11 publications

Neoadjuvant radiochemotherapy of oral cavity and oropharyngeal cancer: evaluation of tumor response by ct differs from histopathologic response assessment in a significant fraction of patients

Neoadjuvant radiochemotherapy of oral cavity and oropharyngeal cancer: evaluation of tumor response by ct differs from histopathologic response assessment in a significant fraction of patients

Preoperative radiochemotherapy and radical resection for stages II–IV oral and oropharyngeal cancer: outcome of 222 patients

Preoperative Paclitaxel/Carboplatin Radiochemotherapy for Stage III/IV Resectable Oral and Oropharyngeal Cancer: Seven-Year Follow-Up of a Phase II Trial

Contact Info

Product

Resources

About